A new prodrug form of Affibody molecules (pro-Affibody) is selectively activated by cancer-associated proteases

Cellular and Molecular Life Sciences

Volumn 72, Issue 7, 2015, Pages 1405-1415

  Sandersjöö, Lisa ^a   Jonsson, Andreas ^a   Löfblom, John ^a  

^a ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

Bacterial display; Cell surface display; Combinatorial protein engineering; Directed evolution; Flow cytometry; HER2; MMP 1; Staphylococcal display

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERSTITIAL COLLAGENASE; PRO AFFIBODY; PRODRUG; UNCLASSIFIED DRUG; AFFIBODY (ZHER2-342)2; HYBRID PROTEIN; PEPTIDE HYDROLASE; PROTEIN BINDING;

ARTICLE; BACTERIAL CELL; BINDING AFFINITY; CANCER CELL; CONTROLLED STUDY; DRUG DESIGN; DRUG PURIFICATION; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG TARGETING; HYDROLYSIS; NONHUMAN; PROTEIN ENGINEERING; PROTEIN EXPRESSION; STAPHYLOCOCCUS CARNOSUS; TISSUE SPECIFICITY; BINDING COMPETITION; CHEMISTRY; ENZYMOLOGY; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; METABOLISM; NEOPLASM; PROTEIN DEGRADATION; SURFACE PLASMON RESONANCE; TUMOR CELL LINE;

BACTERIA (MICROORGANISMS);

BINDING, COMPETITIVE; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; MATRIX METALLOPROTEINASE 1; NEOPLASMS; PEPTIDE HYDROLASES; PRODRUGS; PROTEIN BINDING; PROTEOLYSIS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; SURFACE PLASMON RESONANCE;

EID: 84930903226     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-014-1751-8     Document Type: Article

References (32)

1. Strebhardt K, Ullrich A (2008) Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 8(6):473-480. doi: 10.1038/nrc2394
2. Weiner LM, Surana R, Wang S (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10(5):317-327. doi: 10.1038/nri2744
3. Löfblom J, Frejd FY, Ståhl S (2011) Non-immunoglobulin based protein scaffolds. Curr Opin Biotechnol. doi: 10.1016/j.copbio.2011.06.002
4. Ståhl S, Kronqvist N, Jonsson A, Löfblom J (2013) Affinity proteins and their generation. J Chem Technol Biotechnol 88(1):25-38. doi: 10.1002/jctb.3929
5. Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96(12):1788-1795. doi: 10.1038/sj.bjc.6603813
6. Perez EA (2008) Cardiac toxicity of ErbB2-targeted therapies: what do we know? Clin Breast Cancer 8(Suppl 3):S114-S120
7. Segaert S, Van Cutsem E (2005) Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol Off J Euro Soc Med Oncol/ESMO 16(9):1425-1433. doi: 10.1093/annonc/mdi279
8. Huttunen KM, Raunio H, Rautio J (2011) Prodrugs-from serendipity to rational design. Pharmacol Rev 63(3):750-771. doi: 10.1124/pr.110.003459
9. Overall CM, Dean RA (2006) Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Rev 25(1):69-75. doi: 10.1007/s10555-006-7890-0
10. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N (2000) Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res BCR 2(4):252-257
11. Boström P, Söderström M, Vahlberg T, Söderström K-O, Roberts PJ, Carpén O, Hirsimäki P (2011) MMP-1 expression has an independent prognostic value in breast cancer. BMC Cancer 11:348. doi: 10.1186/1471-2407-11-348
12. Eck SM, Hoopes PJ, Petrella BL, Coon CI, Brinckerhoff CE (2009) Matrix metalloproteinase-1 promotes breast cancer angiogenesis and osteolysis in a novel in vivo model. Breast Cancer Res Treat 116(1):79-90. doi: 10.1007/s10549-008-0085-3
13. Köhrmann A, Kammerer U, Kapp M, Dietl J, Anacker J (2009) Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: new findings and review of the literature. BMC Cancer 9:188. doi: 10.1186/1471-2407-9-188
14. Mannello F (2011) What does matrix metalloproteinase-1 expression in patients with breast cancer really tell us? BMC Med 9:95. doi: 10.1186/1741-7015-9-95
15. McGowan PM, Duffy MJ (2008) Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol Off J Eur Soc Med Oncol/ESMO 19(9):1566-1572. doi: 10.1093/annonc/mdn180
16. Park YH, Jung HH, Ahn JS, Im Y-H (2008) Ets-1 upregulates HER2-induced MMP-1 expression in breast cancer cells. Biochem Biophys Res Commun 377(2):389-394. doi: 10.1016/j.bbrc.2008.09.135
17. Desnoyers LR, Vasiljeva O, Richardson JH, Yang A, Menendez EEM, Liang TW, Wong C, Bessette PH, Kamath K, Moore SJ, Sagert JG, Hostetter, Han F, Gee J, Flandez J, Markham K, Nguyen M, Krimm M, Wong KR, Liu S, Daugherty PS, West JW, Lowman HB (2013) Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Sci Trans Med 5(207):207ra144. doi: 10.1126/scitranslmed.3006682
18. Erster O, Thomas JM, Hamzah J, Jabaiah AM, Getz JA, Schoep TD, Hall SS, Ruoslahti E, Daugherty PS (2012) Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases. J Control Release Off J Control Release Soc 161(3):804-812. doi: 10.1016/j.jconrel.2012.05.035
19. Gerspach J, Müller D, Münkel S, Selchow O, Nemeth J, Noack M, Petrul H, Menrad A, Wajant H, Pfizenmaier K (2006) Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug. Cell Death Differ 13(2):273-284. doi: 10.1038/sj.cdd.4401735
20. Watermann I, Gerspach J, Lehne M, Seufert J, Schneider B, Pfizenmaier K, Wajant H (2007) Activation of CD95L fusion protein prodrugs by tumor-associated proteases. Cell Death Differ 14(4):765-774. doi: 10.1038/sj.cdd.4402051
21. Löfblom J, Feldwisch J, Tolmachev V, Carlsson J, Ståhl S, Frejd FY (2010) Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 584(12):2670-2680. doi: 10.1016/j.febslet.2010.04.014
22. Malm M, Kronqvist N, Lindberg H, Gudmundsdotter L, Bass T, Frejd FY, Höidén-Guthenberg I, Varasteh Z, Orlova A, Tolmachev V, Ståhl S, Löfblom J (2013) Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification. PLoS One 8(5):e62791. doi: 10.1371/journal.pone.0062791
23. Orlova A, Magnusson M, Eriksson TLJ, Nilsson M, Larsson B, Höidén-Guthenberg I, Widström C, Carlsson J, Tolmachev V, Ståhl S, Nilsson FY (2006) Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 66(8):4339-4348. doi: 10.1158/0008-5472.CAN-05-3521
24. Wållberg H, Löfdahl P-K, Tschapalda K, Uhlén M, Tolmachev V, Nygren P-K, Ståhl S (2011) Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand. Protein Expr Purif 76(1):127-135. doi: 10.1016/j.pep.2010.10.008
25. Kronqvist N, Löfblom J, Jonsson A, Wernérus H, Ståhl S (2008) A novel affinity protein selection system based on staphylococcal cell surface display and flow cytometry. Protein Eng Des Sel PEDS 21(4):247-255. doi: 10.1093/protein/gzm090
26. Kronqvist N, Malm M, Rockberg J, Hjelm B, Uhlén M, Ståhl S, Löfblom J (2010) Staphylococcal surface display in combinatorial protein engineering and epitope mapping of antibodies. Recent Pat Biotechnol 4(3):171-182
27. Kronqvist N, Malm M, Göstring L, Gunneriusson E, Nilsson M, Höidén Guthenberg I, Gedda L, Frejd FY, Ståhl S, Löfblom J (2011) Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules. Protein Eng Des Sel PEDS 24(4):385-396. doi: 10.1093/protein/gzq118
28. Götz F (1990) Staphylococcus carnosus: a new host organism for gene cloning and protein production. Soc Appl Bacteriol Symp Ser 19:49S-53S
29. Löfblom J, Kronqvist N, Uhlén M, Ståhl S, Wernérus H (2007) Optimization of electroporation-mediated transformation: Staphylococcus carnosus as model organism. J Appl Microbiol 102(3):736-747. doi: 10.1111/j.1365-2672.2006.03127.x
30. Löfblom J (2011) Bacterial display in combinatorial protein engineering. Biotechnol J. doi: 10.1002/biot.201100129
31. Clendeninn NJ, Appelt K (eds) (2001) Matrix metalloproteinase inhibitors in cancer therapy. Humana Press, New York
32. Löfblom J, Sandberg J, Wernérus H, Ståhl S (2007) Evaluation of staphylococcal cell surface display and flow cytometry for postselectional characterization of affinity proteins in combinatorial protein engineering applications. Appl Environ Microbiol 73(21):6714-6721. doi: 10.1128/AEM.01432-07